Acumen Pharmaceuticals Unveils Enhanced Brain Delivery Technology for Alzheimer’s Antibody in Phase 2 Trial
Acumen Pharmaceuticals announced at the CTAD conference the development of enhanced brain delivery technology for Alzheimer's antibodies, using the transferrin receptor pathway. This aims to improve the efficacy-to-safety ratio of treatments like sabirnetug (ACU193). The company also shared recruitment strategies from the Phase 2 ALTITUDE-AD trial, highlighting effective participant enrollment methods. The findings were presented at the conference, with data available on Acumen's website.
Acumen Pharmaceuticals Inc. announced new research at the 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference, held from December 1-4, 2025, in San Diego and online. The company presented results from a collaborative study with JCR Pharmaceuticals demonstrating improved delivery of amyloid beta oligomer-targeting monoclonal antibodies, including sabirnetug (ACU193), to the central nervous system using the transferrin receptor pathway. This approach is being developed to potentially enhance brain distribution and maximize the efficacy-to-safety ratio of these antibodies. Additionally, Acumen shared findings from the Phase 2 ALTITUDE-AD clinical trial regarding recruitment strategies, identifying site databases and physician referrals as the most effective methods for enrolling participants in early Alzheimer’s disease studies. The results were presented at the conference, and data posters are available on the company’s website. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acumen Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9594769-en) on December 02, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
